We develop antibody-based therapies targeting IL1RAP

See our pipeline

Our goal is to treat cancer as well as inflammatory and autoimmune diseases

See our clinical program

Strong results provide support for our development programs

See our company presentation

2023-11-10 Interview with DiTV

CEO Göran Forsberg comments on the quarterly report

Watch the interview here

2023-10-03 Redeye Autoimmune & Inflammatory Disease Event

David Liberg, CSO Cantargia, presents at Redeye Autoimmune & Inflammatory Disease Event

Watch the interview here

2023-10-02 Interview with Redeye

Redeye interviews CEO Göran Forsberg about new results for nadunolimab monotherapy and IL1RAP as a biomarker presented at AACR

Watch the interview in Swedish here

Press releases

2023-11-30 (R) New number of shares and votes in Cantargia

2023-11-24 Cantargia reports new preclinical data confirming the potential of nadunolimab and CAN10

2023-11-20 (R) Third party withdraws appeal related to Cantargia patent

(R) = Regulatory press releases

Analysis

2023-11-13, Redeye analysis of Cantargia

2023-10-31, Redeye analysis of Cantargia

2023-08-23, Redeye analysis of Cantargia

2023-05-26, Redeye analysis of Cantargia

Current corporate presentation

Other presentations

2023-11-23, Video, Redeye Life Science Day 2023

2023-10-26, Video, BioStock Life Science Summit, Lund

2023-10-25, Video, Økonomisk Ugebrev Life Science Investor Conference, Köpenhamn (In Swedish)

2023-10-09, Presentation, Aktiespararna Småbolagsdagen (Small Cap) i Lund

2023-10-03, Video, Redeye Autoimmune & Inflammatory Disease Event